A cohort study of patients with advanced, unresectable (stage IIIB) metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC) or in relapse starting treatment with Avastin® in combination with chemotherapy as first line treatment of metastatic

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Prospective cohort : - Adult, man or woman patient (age >= 18 years), - With unresectable locally advanced (stage IIIB), metastatic (stage IV) or recurrent non squamous (whenever the histology is not predominantly of squamous cell type) non-small cell lung cancer (NSCLC), and treated in first line setting - Patient starting for the first time a treatment with bevacizumab in first line setting, - Patient having received oral and written information on the study and having no objection to the fact that his (her) personal data will be subjected to data processing. Registry : - Patients with unresectable locally advanced (stage IIIB), metastatic (stage IV) or recurrent non squamous non-small cell lung cancer (NSCLC), and treated in first line setting, - Patients for whom the multidisciplinary committee decided to not initiate a treatment with bevacizumab, - Inclusion in the registry had to be consecutive during the first three months of study participation for each investigator.","clusion_E":""}